Clonidine is an anti-hypertensive medication which acts as an alpha-adrenergic receptor agonist. As the noradrenergic system is likely to support cognitive functions including attention and executive control, other clinical uses of clonidine have recently gained popularity for the treatment of neuropsychiatric disorders like attention-deficit hyperactivity disorder or Tourette syndrome, but the mechanism of action is still unclear. Here, we test the hypothesis that the noradrenergic system regulates the activity of subthalamo-motor cortical loops, and that this influence can be modulated by clonidine. We used pharmacological manipulation of clonidine in a placebo-controlled study in combination with subthalamic nucleus-deep brain stimulation (STN-DBS) in 16 Parkinson's disease patients performing a reaction time task requiring to refrain from reacting (proactive inhibition). We recorded electroencephalographical activity of the whole cortex, and applied spectral analyses directly at the source level after advanced blind source separation. We found only one cortical source localized to the supplementary motor area (SMA) that supported an interaction of pharmacological and subthalamic stimulation. Under placebo, STN-DBS reduced proactive alpha power in the SMA, a marker of local inhibitory activity. This effect was associated with the speeding-up of movement initiation. Clonidine substantially increased proactive alpha power from the SMA source, and canceled out the benefits of STN-DBS on movement initiation. These results provide the first direct neural evidence in humans that the tonic inhibitory activity of the subthalamocortical loops underlying the control of movement initiation is coupled to the noradrenergic system, and that this activity can be targeted by pharmacological agents acting on alpha-adrenergic receptors.
Clonidine acts as an a-adrenergic receptor agonist, and is commonly prescribed as an anti-hypertensive medication. As it increases noradrenergic (NA) outflow from the locus coeruleus to the prefrontal cortex and stimulates directly presynaptic a-2A receptors in the cortex, clonidine is also likely to have effects on various functions that rely on the NA system. For instance, it has also been shown to be useful in treating some symptoms like attentional dysfunctions and impulsivity observed in attention-deficit hyperactivity disorder and Tourette syndrome (Lichter and Jackson 1996; Ming et al. 2011) . However, the mechanisms of action of clonidine, and more generally of the whole class of pharmacological agents targeting the NA system, are still unclear. The main reason is that it is particularly challenging to investigate the functional roles of the NA system in the living human brain as there is still no satisfactory selective positron emission tomography radiotracer for in vivo imaging. This lack of basic knowledge about the functional networks that are modulated by the NA system impedes the potential spectrum of application of pharmacological agents acting on a-adrenergic receptors. However, recent studies have given glimpses of the potential of this class of drugs by suggesting that the NA system plays a critical role in specific cognitive and motor functions, as well as in the physiopathology of other diseases like Parkinson's disease (PD) and Alzheimer's disease (Zarow et al. 2003; Marien et al. 2004; Fornai et al. 2007; Chamberlain and Robbins 2013; Mather and Harley 2016; Rae et al. 2016; Borodovitsyna et al. 2017; Nahimi et al. 2017) .
Here, we focus on movement initiation disorders and, to this aim, study PD patients. The interest in PD is double. First, movement initiation disorders represent a major symptom of the disease which is both difficult to isolate (see Schilder et al. 2017 ) and difficult to treat. Second, it becomes possible, in implanted PD patients, to manipulate the activity of the subthalamic nucleus (STN), a small but critical basal ganglia nucleus whose activity cannot be easily recorded with classical neuroimaging tools. Our understanding of the neural bases of movement initiation and related disorders is still incomplete (Gauntlett-Gilbert and Brown 1998; Rodriguez-Oroz et al. 2009 ). This is partly due to the fact that there is no unified use of terminology for the range of disturbances of voluntary movement and, hence, strong potential confounds regarding the underlying dysfunctional neural mechanisms (Schilder et al. 2017) . This is also partly due to the fact that a number of important questions about the basal ganglia (BG) circuitry remain unresolved, including the issue of the exact role of STN, one of the two input stations of the BG (Nambu 2008; Obeso and Lanciego 2011; Haynes and Haber 2013; Jin et al. 2014) .
In PD, impairment of movement initiation has mostly been referred to as akinesia (e.g., Hallett 1990) . It is a cardinal symptom of the disease that is not fully alleviated by dopaminergic medication (Schubert et al. 2002; Favre et al. 2013; Fox 2013) . Here, we refer to slowness in movement initiation, which is not to be confounded with slowness of movement execution, that is, bradykinesia (Schilder et al. 2017) . Slowness in movement initiation is associated with dysfunctions of movement preparation, an ensemble of sensorimotor and executive processes that build up the command to move and control its triggering before the movement is initiated (Alexander and Crutcher 1990; Kaufman et al. 2014) . Behaviorally, it is assessed by means of reaction time (RT) measures.
1 Movement initiation relies on modular cortico-basal ganglia-thalamocortical loops. It involves distinct pathways of the motor circuit through which cortical inputs enter the striatum, are forwarded to the thalamus which projects back to the cerebral cortex. These different pathways exert antagonist effects on motor cortical activity. The cortico-striato-pallidal direct pathway relays activating signals from the motor cortices. These signals induce inhibition in the internal segment of the globus pallidus (GPi) and substantia nigra pars reticulata (SNr) that results in increased activation of the ventrolateral nucleus of the thalamus which, in turn, amplifies motor cortical activity. The indirect pathway has opposite effects on the GPi/SNr since it reinforces the default inhibitory outflow of the basal ganglia. Its activation leads to a reduction of activity in the motor cortices to prevent unwanted movements. The indirect pathway involves the STN in a cortico-striato-pallido (external, GPe)-STN-pallidal (GPi) circuit. Movement disorders of basal ganglia origin are thought to result from imbalanced activities between the two pathways (e.g., Albin et al. 1989) . Importantly, another pathway, the hyperdirect pathway, also involves the STN, which receives direct cortical information that gets relayed to the GPi/SNr (Nambu et al. 2002; Nambu 2004) . This pathway could play a role in relaying fast signals instructing to inhibit ongoing actions, or in switching from controlled to automatic sensorimotor processing by modulating the balance between facilitation and attenuation of motor cortical activity Isoda and Hikosaka 2007; Aron 2011) . Since the STN receives direct projections from both motor and non-motor cortical areas, it likely plays a pivotal role as an interface between executive and motor systems in basal gangliathalamocortical loops (Benarroch 2008) , either via the slow indirect pathway or via the fast hyperdirect pathway. However, despite clues from subthalamic nucleus-deep brain stimulation (DBS) studies (Favre et al. 2013; Benis et al. 2014; Albares et al. 2015a; Faggiani et al. 2015) the exact role of the STN remains poorly understood.
1 Although bradykinesia might also partly be due to dysfunctions of movement preparation, it mostly results from a failure of basal ganglia output to reinforce the cortical mechanisms that execute the commands to move (Berardelli et al. 2001) . Behaviorally, bradykinesia is assessed by means of movement duration measures, but that is outside the scope of this paper.
Difficulties initiating movements in PD are generally interpreted as a motor and dopaminergic dysfunction. Distorting signals from sensorimotor, dopamine-deprived circuits would induce increased tonic inhibition from basal ganglia output, and would result in impaired automatic movements (Redgrave et al. 2010) . According to this view, PD patients would be trapped in goal-directed control to overcome the inhibitory distortion from the malfunctioning stimulus-response control circuits in the basal ganglia. It is noteworthy that this compensatory mechanism is accompanied by increasing fatigue because this level of goal-directed input is difficult to sustain (ibid). A slightly different view suggests that PD patients would be trapped in goal-directed control because of specific executive dysfunction, not just to compensate for impaired automatic movements (Ballanger et al. 2009; Favre et al. 2013; Albares et al. 2015a; Criaud et al. 2016) . This executive disorder concerns proactive inhibition, a function which is intended to inhibit movement triggering mechanisms in the absence of stimulation in uncertain environments. The goal of this function is to prevent undesired automatic responses to upcoming stimulation (Aron 2011; Criaud et al. 2012 Criaud et al. , 2017 Jaffard et al., 2007 , Jaffard et al. 2008 Li 2015) . It involves a cortical network which is more active when subjects must refrain from reacting to external events and which deactivates to allow the response to be triggered (Fig. 1a) . This network comprises notably the supplementary motor area (SMA) and the dorsomedial prefrontal/anterior cingulate cortex, which have direct connections to the STN (Benarroch 2008) . PD patients would be locked into a mode of executive control Fig. 1 (a) Theoretical assumptions and (b) electrophysiological signature of proactive inhibitory control. The simple reaction time (RT) task probes the ability to refrain from reacting automatically to visual targets by means of proactive inhibitory control, a pivotal mechanism consisting in gating movement initiation in the pre-stimulus period when the context is uncertain. (a) When the context is uncertain, inhibitory control is implemented in the absence of stimulation. When a target is presented, inhibition must be released before a goal-directed movement can be triggered. This time consuming mechanism generates long latency responses. When the context is predictable, healthy subjects do not set proactive inhibitory control, and provide automatic short latency responses. Conversely, Parkinson's disease patients show abnormally enhanced activity within the proactive inhibitory network leading to difficulties initiating movements (delayed responses, Criaud et al. 2016 ). As inferred from behavioral studies, the effect of STN-DBS may consist in reinstating the ability to release proactive inhibitory control in the absence of stimulation when the context does not require action restraint (Favre et al. 2013; Albares et al. 2015a) . Clonidine could impede the positive action of STN-DBS on movement initiation by blocking the ability to release proactive activity within the inhibitory network (Albares et al. 2015a) . (b) Electroencephalography (EEG) offers the possibility to track relevant spectral activity, directly at the source level after blind source separation and DBS artifacts removal. Time course of a power on a trial-by-trial basis in healthy subjects. Trials are sorted according to RT (black curve) when proactive inhibition is set, an increase in tonic a power is observed during the pre-stimulus period that desynchronizes when the stimulus has been identified. This proactive activity predicts RT.
which maintains inappropriate tonic, proactive inhibition over movement triggering in situations that do not require action restraint (Favre et al. 2013; Albares et al. 2015a) . In accordance with this view, difficulties initiating movements are associated with pathological overactivity within the proactive inhibitory brain network (Criaud et al. 2016) . Deep brain stimulation of the subthalamic nucleus would act by regaining control of the state of 'self-initiated automaticity' (ibid). However, the functional modulations accounting for the executive benefits of STN-DBS on movement initiation have not been identified.
In contrast to the acknowledged role of dopamine in motor processes, the dysfunction of proactive inhibitory control leading to delayed movement initiation in PD, and its restoration by STN-DBS, does not appear to be dopaminergic-dependent (Favre et al. 2013) . A recent behavioral study in PD combining pharmacological manipulation using clonidine and STN-DBS suggests that the NA system plays a role in the positive action of STN-DBS on movement initiation latency (Albares et al. 2015a) . However, there is still no direct neural evidence in humans that the NA system modulates the activity of the subthalamic-cortical loops involved in motor control. This is the first goal of this study. An associated objective is to test whether clonidine, an antihypertensive medication which acts as an a-adrenergic receptor agonist, can regulate the activity of the corticobasal ganglia loops underlying the executive control of movement initiation.
It is essential to assess DBS-induced modulations of brain activity to provide such neural evidence (Okun 2014; Udupa and Chen 2015) . Yet, several obstacles impede the identification of the different cortico-subthalamic networks and neurotransmitter systems involved in the mechanisms of action of STN-DBS. First, it is a major technical challenge to record cortical dynamics while applying DBS. Second, controversy surrounds the interpretation of the balancing activity in these circuits due to difficulties in disentangling motor and inhibitory processes with neuroimaging data (Logothetis 2008) . Here, we use electroencephalography (EEG), which offers: (i) the opportunity to assess cortical dynamics during DBS, and (ii) strong discriminative power regarding the nature of brain modulations by means of the analysis of the spectral signatures of the functions of interest.
Here, we analyzed EEG data from PD patients in a placebo-controlled experiment investigating the effects of NA attenuation by clonidine (a2-adrenergic receptor agonist) under two conditions of STN-DBS (OFF vs. ON). The behavioral results of this experiment have been described in a former publication (Albares et al. 2015a) . Recent methodological advances from our group allowed us to remove DBS-induced electrical artifacts (Allen et al. 2010; revised) , to separate/localize significant sources on the basis of the mixed signal recorded on the scalp Boulinguez 2013, 2016) , and to apply advanced signal processing methods to unravel the time course of concurrent excitatory and inhibitory activity (Albares et al. 2015b ).
Material and methods

Participants
Eighteen parkinsonian patients (aged 59.6 AE 5.0 years old, five females, with normal or corrected-to-normal vision) treated with bilateral STN stimulation were enrolled. The sample size was determined on the basis of the expected differences informed by former behavioral results using the same design in STN-DBS patients.
2 The group size was also determined in agreement with former specific recommendations regarding EEG group blind source separation analyses . Patient recruitment was conducted according to the following inclusion criteria: age between 40 and 70 years old, patients with idiopathic dopa-sensitive Parkinson's disease, treated with STN-DBS for at least 3 months, under stable pharmacological anti-parkinsonian treatment for at least 2 months, and presenting no contraindication for taking clonidine (no depression, no heart disease, no lactose intolerance). Exclusion criteria were: sign of depression or other neurologic or psychiatric pathology, pharmacological treatment with cerebral or psychic impact, substance abuse according DSM-IV-TR (excluding tobacco), pregnancy or breastfeeding. The implantation of the electrodes (Model 3389; Medtronic, Minneapolis, MN, USA) was performed under local anesthesia, guided by stereotactic magnetic resonance imaging, and microelectrode recordings. The accurate placement of the electrodes was confirmed on post-operative CT scan. The electrodes were connected to a pulse generator (Kinetra or Soletra, Medtronic). The main demographic and clinical characteristics of the patients, the stimulation parameters used, the levodopa equivalent dose, and the effects of STN stimulation on the Unified Parkinson's Disease Rating Scale (UPDRS) motor scores are presented in Table 1 . All these parameters were used as covariates in order to examine potential subgroups and interactions. The patients did not exhibit major signs of tremor and were not demented (MATTIS > 130). Of note, two patients (P3, P8) presented pathological gambling and compulsive shopping tendencies while one (P14) reported dopaminergic addiction and nocturnal hyperactivity well before STN-DBS surgery (at least 3 years ago). These symptoms have been totally suppressed by stopping dopaminergic agonists. Furthermore, all patients were submitted to 2 We used the RT values observed for PD patients ON STN-DBS vs. PD patients OFF STN-DBS in preliminary data (Favre et al. 2013) , in the same conditions of interest as those described in this study (Go mixed-block vs. Go pure-block). The estimated sample size n was calculated as the solution of:
where d = delta/sd = 50 ms/40 ms, a = 0.05, power = 1 -b = 0.8, tv, p is a Student t quantile with v degrees of freedom and probability p. n is rounded up to the closest integer. Given a desired power of 80%, and a predetermined Type I error rate a of 5%, the number of patients required to evidence a RT difference of 50 ms between ON-and OFF -DBS conditions was fixed to 16.
the neuropsychological Ardouin scale of behavior in Parkinson's disease (Ardouin et al. 2009 ), which assesses changes in usual activities, psychiatric tendencies, and evaluation of both apathic and appetitive modes. Hyperdopaminergic abnormalities were not reported in any patient. Participant consent was obtained according to the code of ethics of the World Medical Association (Declaration of Helsinki) and the experimental protocol was approved by the local Ethical Committee in Biomedical Research (Comit e de Protection des Personnes sud est IV, N_ CPP 12/039). This study was pre-registered before being conducted on the clinicaltrials.gov database under the trial record number NCT01796483.
Behavioral task and procedure
Patients performed a cue-target RT task fully described elsewhere (Albares et al. 2015a) . The experiment was intended to test the ability of patients to initiate simple movements in response to visual targets while maintaining their capacity to refrain from reacting to other visual stimulations (Fig. 2) . Specifically, the ability to react to visual stimuli was assessed in separate blocks of trials in which only visual targets were presented (inducing no uncertainty about upcoming stimuli, that is, no need for subjects to refrain from reacting). In this condition (no-cue trials), short RTs are expected because subjects can react automatically to any upcoming event (Albares et al. 2015a; Fig. 1b) . This condition represents the control condition in which healthy subjects do not implement proactive inhibitory control (Criaud et al. 2012) . The ability to refrain from reacting to non-targets was assessed in other blocks of trials mixing targets and cues (inducing uncertainty about upcoming stimuli, i.e., requiring proactive inhibitory control). In this context, long RTs are expected when the target is not preceded by a warning cue because subjects cannot react automatically to any upcoming event. They need first to release proactive inhibition after they have identified the target stimulus. Then only, they produce delayed volitional response (Albares et al. 2015a; Fig. 1b) . Stimuli were projected on a screen placed 50 cm away from the participants' eyes. While keeping their gaze fixed on a central fixation point, participants were asked to react as quickly as possible to a visual target that might or might not be preceded by a neutral warning signal by pressing a button with the right index finger (Fig. 2) . In the mixed-block of trials, cue and no-cue trials were presented randomly. In the pure-block, only no-cue trials were presented. Before starting recording, two training sessions were presented: one pure-block (48 trials) and one mixed-block (96 trials). Recordings were performed in four following blocks (two pure-blocks of 48 trials each and two mixed-blocks of 96 trials each). The order of these four blocks was counterbalanced across participants and for each condition of STN-DBS and Drug. Each subject performed 288 trials for each session of stimulation and drug, equal to 1152 trials in total (four sessions).
Drugs procedure NA manipulation was realized in a simple blind design, placebocontrolled study, using a 150 lg oral dose of clonidine (a2-AR agonist). Clonidine is highly selective, exerts potent agonistic effects at pre-synaptic a-2 receptors, and has optimal kinetics with respect to the duration of our protocol (Delaville et al. 2011) . Specifically, clonidine decreases NA release through pre-synaptic a2-AR activation. Each patient was tested in four experimental sessions combining all conditions of stimulation (STN-DBS ON; STN-DBS OFF) and drug (Clonidine; Placebo). The first (S1) and the second (S2) sessions were separated by 24 h. The third (S3) and fourth (S4) sessions took place 3 months later, separated by 24 h. Since the long half-life of clonidine does not allow complete withdrawal from the body from one day to the next, patients always received placebo first (at S1 and S3), and then received a clonidine (at S2 and S4, 150 mg oral dose). In this simple blind design, patients were blinded to the drug condition (Clonidine; Placebo), while clinicians were aware that placebo was always given on the first day and clonidine on the second day. Patients were tested in the morning (at 9 am) on two consecutive days, with and without STN-DBS treatment (ON and OFF conditions) while taking their usual anti-parkinsonian drugs. Randomization blocks were used to allocate subjects to experimental groups in order to counterbalance the order of the ON and OFF conditions of STN-DBS across participants. The stimulator was switched off in the OFF condition 30 min before testing. The fact that patients were tested at the same time schedule in the ON and OFF conditions ensured that the effect of dopaminergic medication was identical in both states (see Table 1 for the demographic characteristics). The drug was administered 90 min before testing to maximize the effect. Since clonidine has well-established anti-hypertensive properties, the blood pressure was monitored every 30 min from intake time to 1 h after the experiment. Two patients were excluded from the analysis during the course of the study because the DBS battery housing was infected and removed between the S1/S2 and S3/S4 sessions. EEG analyses were conducted only on the 16 patients who have completed all experimental sessions (aged 59.3 AE 5.2 years old, four females; Table 1 ).
EEG
EEG data acquisition procedure
The Biosemi TM ActiveTwo Mk2 system (31.25 nV resolution) (Biosemi B.V., Amsterdam, Netherlands) was used to record EEG data from 128 electrodes mounted in an elastic cap at Biosemi TM ABC system standard locations. Six additional external electrodes were added: four temporal electrodes (Biosemi spherical coordinates: Phi À103.5 Theta À18 À36, and Phi 103.5 Theta 18 36), and two electrodes attached to the outer canthi of the left and right eyes (Phi 103.5 À103.5 Theta 81 À81). The Common mode sense Fig. 2 Experimental protocol. The cuetarget reaction time (RT) task is composed of two blocks of trials: A mixed-block in which cue and no-cue trials are presented randomly, and a pure-block in which only no-cue trials are presented. Since the effects of the disease (patients vs. age matched controls) and the effects of subthalamic deep brain stimulation (ON vs. OFF) have been observed only in the pureblock condition (Favre et al. 2013; Albares et al. 2015a; Criaud et al. 2016) , the analyses of this study are restricted to this single pure-block condition.
(CMS) active electrode and the Driven right leg (DRL) passive electrode of the ActiveTwo system were used instead of classical ground electrodes of conventional systems (these two electrodes form a feedback loop driving the average potential of the subjectthe Common Mode voltage -as close as possible to the analog-todigital reference voltage in the AD-box). All electrode offsets were kept below 20 mV. EEG data were recorded at a sampling rate of 2048 Hz. Offline, data were high-pass filtered above 1 Hz, low-pass filtered at 95 Hz, notch filtered at 50 Hz, and down-sampled to 1024 Hz. Then, data were epoched from 1500 ms before stimulus onset to 1000 ms after stimulus onset.
EEG data pre-processing and analyses
The entire pipeline is schematized in Fig. 3 . We applied recent methodological developments from our group to: (i) remove DBS artifacts , (ii) apply group Blind Source Separation (gBSS), a method that directly identifies the components that are consistently expressed in the population (Lio and Boulinguez 2013; Albares et al. 2015b; Huster et al. 2015) . The other benefits of using gBSS include better sensitivity for discrimination between groups of subjects or sessions that are separated in time, which is particularly convenient for the present clinical investigation, and more efficient localization of these components .
First, data were filtered in order to remove the DBS-induced electrical noise that scrambles the low magnitude of the EEG signal. This step is critical since the available methods for filtering DBS artifacts are neither easy to use nor fully satisfactory. Here, we combined different techniques for optimal filtering (anti-aliasing analog and digital low-pass standard filtering, plus an optimized frequency-domain filtering technique, Hampel method) (Allen et al. 2010) . To this aim, we used open-source toolbox DBSFILT .
Then, for each subject, corrupted epochs and artifacts (blinks, eye movements, electrical noises) were automatically detected and rejected using an Higher Order Statistics-based BSS algorithm (Infomax ICA) with EEGLAB (Delorme and Makeig 2004) and the FASTER toolbox (Nolan et al. 2010) .
gBSS: First, we concatenated individual trials obtained from our 16 patients. Then, we applied gBSS to unmix the signals contributing to the overall electrical activity recorded on the scalp. To this end, we used a robust second-order statistics-based algorithm to optimize separation: UW-SOBI was privileged over more popular but less robust higher order statistics-based algorithms (Yeredor 2000; Lio and Boulinguez 2013) . Among the 134 Independent Components (ICs) identified, we selected for further analyses only the most consistent components across subjects. To this aim, we used a standard consistency test adapted from previous studies (Congedo et al. 2010; Ponomarev et al. 2014) . This method consists in separating the whole group into two subsamples of nine subjects matched for performance, and applying a test-retest strategy to select only ICs that are replicable across subjects. Among all possible combinations of two groups of nine subjects, we selected the combination with the more similar delta mean RT between the no-cue, mixed-block condition and the no-cue, pureblock condition in the Placebo condition and in the Clonidine condition. In consequence, the probability to obtain, by chance, two groups of nine subjects more similar than these two is below 1 9 10
À5
. Then, in addition to the whole subjects gBSS (G_all), two supplementary gBSSs were performed, one on group 1 (G1) and one on group 2 (G2). Finally, the ICs obtained from G_all, G1, and G2 decompositions were matched. To this aim, we used the Pearson correlation scores between the weights of the mixing matrices, with the following algorithm:
• ICs are sorted in decreasing order of explained variance.
• For i, from 1 to the number n of ICs; n triplets of matched ICs were built by searching in G1 IC_1 (i) and in G2 IC_2 (i) the components that are most similar with the component IC_all (i) of G_all.
• To assess the quality of IC_all (i), for each triplet of components [IC_1 (i); IC_2 (i); IC_all (i)], a quality index based on the similarity of the spatial signature of the components was used: Q_i=|q_pearson (IC_1 (i), IC_2 (i))|9100,
• For each quality index Q_i, a p-value was calculated considering all possible combinations of two ICs randomly extracted from two different ICA/BSS decompositions. Only group ICs with a quality index Q_i > 70% (p < 0.01) were considered as reliable for further analysis.
Deconcatenation and normalization for between-subject's analyses: The consistent ICs obtained at the group level served as a filter to get back to the individual level of analysis. This step is essential because each patient was tested in four different experimental sessions separated by at least 24 h, meaning that different electrode set-ups were used for each single subject. This prevents from comparing directly the absolute potentials between the experimental conditions. This step-back to individual analyses allows individual data normalization, a prerequisite for between-subjects analyses in these circumstances. The mean relative power within each frequency band was thus calculated with respect to the total power of the EEG signal (whole spectrum) for each single source/subject.
Statistical analyses of pre-stimulus activity
The analysis consisted in assessing STN-DBS-induced modulations and clonidine-induced modulations of the relative spectral power during the pre-stimulus period, within each frequency band of the 14 sources that are consistent across subjects. The time window used for the analysis was restricted to the [500-0 ms] pre-stimulus period. Then, the effect of STN-DBS was tested in the placebo condition by means of a non-parametric Wilcoxon signed-rank test for matched samples (ON DBS/Placebo vs. OFF DBS/Placebo). The effect of Drug was tested in the ON STN-DBS condition by means of a non-parametric Wilcoxon signed-rank test (ON DBS/Clonidine vs. ON DBS/Placebo). In accordance with our predictions based on the behavioral results, all tests were one-tailed. p values < 0.05 (Bonferroni corrected) were considered significant.
Visualization
The absolute power within each frequency band was used for visualization of the temporal dynamics of brain recordings. Initially, single-trial power modulations were estimated separately for each frequency band of the selected sources. In order to get optimal time/ frequency resolution within delta/theta (1.5-7.5 Hz), alpha (7.5-13.5 Hz), beta (13.5-30.5 Hz), low gamma (30.5-44.5 Hz), and high gamma (57.5-77.5) band activities, five Elliptic Infinite Impulse Response (IIR) band pass filters were designed with the Matlab TM signal processing toolbox. Relatively large pass band widths were set to get optimal time resolution, that is, optimal estimation of the temporal dynamics of the band, thanks to the Hilbert transform. First, each trial was filtered with the corresponding filter in both forward and reverse directions to ensure zero-phase distortion. Second, the complex analytic signal of each filtered trial was derived by the Hilbert transform (Matlab TM Hilbert function). Third, the amplitude envelope of the signal was computed by taking the absolute magnitude of the complex waveform. The time window was restricted to the 1000 ms prestimulus to 800 ms post-stimulus in order to avoid edge effects/ transient responses of digital filters. Finally, for visualization only, a trial moving average smoothing was applied (windows length: 300). The time course of absolute a power in the SMA was displayed in a figure aggregating all subjects and all trials sorted as a function of RT (Fig. 4c) .
Selection of the sources supporting proactive control Importantly, in this paper, no a priori assumption is made about the brain regions and the frequency bands that may support the effect. Thus, rather than using a region/frequency of interest approach, preference is given to a blind strategy consisting in testing all sources that have been separated, within each frequency band.
Analyses of the temporal dynamics of the signal are required to identify the sources that desynchronize after stimulus presentation, that is, the sources that match the predictions of the theoretical model (Fig. 1b) . Guidelines for assessing the cortical brain dynamics of response inhibition with EEG are summarized in Albares et al. (2015b) . In sum, we compared the mean power of the 500 ms pre-stimulus period to the mean power of the 100 ms pre-RT period on a single-trial basis (aggregate data) by means of Kruskal-Wallis tests and post hoc testing (p < 0.05 Tukey-Cramer corrected). A significant decrease is supposed to index stimulusinduced desynchronization. A lack of significant difference means that the effect (either DBS or Drug) previously observed on the pre-stimulus period is a global effect not related to proactive control.
IC Source localization
Finally, the 3D distribution of the selected source current densities was estimated by means of the sLoreta software (Pascual-Marqui 2002). The head model used for this analysis was obtained by applying the BEM method to the MNI152 template (Mazziotta et al., 2001) . The 3D solution space was restricted to cortical gray matter and was partitioned into 6239 voxels with a spatial resolution of 5 mm. Then, the sLoreta solution of the inverse problem was computed using an amount of Tikhonov regularization optimized for an estimated Signal/ Noise Ratio of 100.
Results
Behavior (RT)
Results of interest for this study are summarized in Fig. 4(b) . We previously showed that both the effect of the disease, the effect of STN-DBS, and the effect of pharmacological manipulation are restricted to the specific situation in which patients are supposed to provide fast automatic responses, that is, not to implement proactive inhibitory control (no-cue trials presented in separate blocks) (Albares et al. 2015a) . In this condition, patients OFF stimulation behave exactly the same way as when they explicitly have to refrain from reacting (Fig. 1a) . This suggests that slowness in movement initiation in PD is due to the fact that patients are locked into a mode of executive control maintaining inappropriate inhibition over response tendencies. STN-DBS was found to restore a normal pattern of response, that is, short RT for no-cue trials presented aside from non-target stimuli versus long RT for no-cue trials presented in blocks of trials mixing target and non-target stimuli. In other words, STN-DBS reinstates the ability to voluntarily release the default, executive control mechanism which normally refrains from reacting in uncertain contexts. Finally, clonidine was found to specifically impede the positive action of STN-DBS on movement initiation. These behavioral data clearly point out that there is only one experimental condition which is relevant to the present issue (no-cue trials in a predictable context), and we therefore focus on this condition in describing the modulations of brain activity (Fig. 1a) . The reader is referred to Albares et al. (2015a) for a comprehensive analysis of the exhaustive behavioral data and detailed statistics. To summarize, under placebo and for the relevant condition, RT is shorter when STN-DBS is ON than when it is OFF (488 vs. 391 ms, respectively, p < 0.05). Under Clonidine, however, RT remains at a pathological value when STN-DBS is ON, compared to Placebo (484 vs. 391 ms, respectively, p < 0.05). Complementary analyses reveal no significant influence of the levodopa equivalent dose on this effect (Appendix S1).
EEG
After the test-retest procedure, 14 reliable ICs were detected (Q_i > 70%; p < 0.01). Only two of these sources revealed significant effects of STN-DBS and/or Drug.
The first source, centered on the SMA (Fig. 4a) , showed significant modulations of pre-stimulus activity matching the pattern of desynchronization predicted by the proactive model of response inhibition in the alpha band. Mean relative alpha power was significantly attenuated when STN-DBS was switched ON with respect to the OFF state (0.0244 A.U. vs. 0.0287 A.U., respectively, p < 0.05). Under combined clonidine and DBS, this alpha activity increased up to the level characterizing the pathological state (i.e., the OFF STN-DBS state) (0.0274 A.U. ON DBS/ Clonidine vs. 0.0244 A.U. ON DBS/Placebo, p < 0.05). (Fig. 4b and c) .
The second source, centered on the cuneus, showed significant modulations of pre-stimulus activity in the beta band. Yet, this activity did not match the expected pattern of desynchronization (Appendix S2).
Discussion
Animal and clinical studies have recently provided clues suggesting a NA origin of some dysfunctions of movement initiation (Delaville et al. 2011 (Delaville et al. , 2012a Chamberlain and Robbins 2013; Espay et al. 2014; Kehagia et al. 2014; Albares et al. 2015a; Rae et al. 2016) . Direct projections from the LC to the STN might support interactions between the NA, the motor and the executive systems (Parent and Hazrati 1995) . There is now consistent evidence that the STN receives NA innervation in rodents (Arcos et al. 2003; Belujon et al. 2007) . Even more recently, NA innervation of the STN has been shown in primates, with convincing demonstration that the partial loss of NA innervation of the STN in monkeys rendered parkinsonian by chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) could contribute to STN dysfunctions in PD (Masilamoni et al. 2017) . In humans, it has also been suggested that the modulatory action of the NA system might be mediated by the STN-cortical loops (Albares et al. 2015a; Faggiani et al. 2015; Faggiani and Benazzouz 2017) . This was especially inferred from the observation of interaction between pharmacological manipulation and DBS on behavior provided in the first report of the present project (Albares et al. 2015a) . However, there was no direct neural-based evidence in humans until the analysis of the present electrophysiological data.
Key inputs
The first original contribution of this study is that brain activity changes induced by stimulation further support the hypothesis that proactive inhibition is restored to normal function by STN-DBS. Different arguments can be put forward: First of all, modulations of electrophysiological activity during the pre-stimulus period are observed in the SMA, a key cortical region which is uniquely positioned to play a pivotal role in the loops between the basal ganglia and the motor cortex (Nambu et al. 1996; Nachev et al. 2008; Lindenbach and Bishop 2013) , and which is directly involved in proactive control (Jaffard et al. 2008; Chen et al. 2010; Criaud et al. 2017) and related disorders in PD (Criaud et al. 2016) . Second, these changes are observed in the critical alpha band, which indexes an active inhibitory mechanism relying on rhythmic local fluctuations of GABAergic inhibitory interneurons (L} orincz et al. 2009; Jensen and Mazaheri 2010; Haegens et al. 2011) . Third, behavioral and brain activity changes are consistent: the decrease in alpha power under STN-DBS is associated with a decrease in RT (Fig. 4) .
The second original contribution of this study is that the cancelation of STN-DBS behavioral effects (as measured through movement initiation latency) by clonidine is associated with an increase in proactive alpha power in the SMA. Remarkably, this increase is observed within the source whose proactive alpha activity is precisely reduced by STN-DBS (Fig. 4b) . In other words, under clonidine the abnormal proactive inhibitory activity of the SMA no longer benefits from the positive effect of STN-DBS, but returns to a pathological state. Taken together, the behavioral observations and brain activity recordings are highly consistent with the hypothesis that a single function, probably proactive inhibitory control, is differently modulated by STN-DBS and clonidine.
Clues about the role of the NA system in inhibitory control and related disorders Our data suggest that the NA system might have a more subtle and specific function in the control of behavior than the non-specific role it is traditionally supposed to play in cognition (e.g., arousal, Chamberlain and Robbins 2013) . Nevertheless, classical non-specific effects of NA manipulation were also observed in the form of a decrease in beta band power in the cuneus in the clonidine condition (Appendix S2). This beta modulation in the occipital cortex does not match the predictions of the proactive inhibitory control model since beta power does not desynchronize after stimulus presentation. However, this modulation is very consistent with the classical functions attributed to the NA system, such as arousal, attention, and vigilance (Chamberlain and Robbins 2013). Interestingly, a reverse effect -a significant increase in beta activity in posterior regions -was observed in another study focused on attention and the NA system but using atomoxetine, a selective NA reuptake inhibitor presenting the opposite effect of clonidine (Alegre et al. 2013) . This attentional effect might contribute to the overall effect of clonidine on behavior in our own results, but does not interact with the effect of STN-DBS. It therefore does not challenge our interpretation of the interaction between STN-DBS and NA manipulation on movement initiation (Albares et al. 2015a ). However, an additive effect of fatigue cannot be ruled out when the level of goal-directed input is inappropriately sustained (Redgrave et al. 2010 ).
Clues about the functional coupling of the STN and the NA system Although the anatomic and functional coupling of the STN to the NA system has been suggested in animal studies (Canteras et al. 1990; Belujon et al. 2007; Delaville et al. 2012b; Faggiani et al. 2015) it has not been consistently evidenced in humans yet. Only one case report of three PD patients who received an intravenous beta-blocker to reduce blood pressure during DBS surgery is available (Coenen et al. 2008) . In this pioneer study, the bursting spiking activity of the STN was found to be temporarily dampened by the administration of a beta1-selective adrenoceptor antagonist, suggesting that NA projections may have a significant influence on STN activity. In our study, the modulation of SMA by the combined effects of clonidine and STN-DBS, a specific a2-adrenergic receptor agonist, provides further arguments that the NA system might be involved in the functioning of basal ganglia-thalamo-cortical loops (Faggiani and Benazzouz 2017) . Taken together, these human data strongly suggest that the efficiency of STN-DBS on movement initiation and associated cortical activity is NA-dependent, that is, that the modulatory action of the NA system on executive control might be mediated by the STN-SMA loop. However, in this study, the executive effect is restricted to the inhibition of a simple motor response to a simple visual stimulus. This basic mechanism does not cover the wide range of executive dysfunctions that are observed in PD (Dirnberger and Jahanshahi 2013) , and that might be related to the NA system (Chamberlain and Robbins 2013) . Future studies should examine how current findings can account for a larger range of executive dysfunctions using appropriate neuropsychological tests.
Direct versus indirect effects of NA modulation
Importantly however, it is likely that the effect of clonidine administered by oral route does not rely exclusively on a direct effect of NA modulation of the STN through a2-adrenergic receptors (Unnerstall et al. 1984) . Besides its high selectivity for a2 autoreceptors (Starke et al. 1975; Starke 2001; Gilsbach and Hein 2008) , clonidine also acts on heteroreceptors of nonadrenergic neurons both in the peripheral and central nervous system (Starke 1977; Schlicker and G€ othert 1998) . In particular, this drug is also an a1-receptor agonist (Eshel et al. 1990) as well as an imidazoline receptor agonist (Ernsberger et al. 1987; Reis and Piletz 1997) . Overall, clonidine triggers a cascade of events that may lead to inhibit the release of many neurotransmitters including serotonin (Feuerstein et al. 1985 (Feuerstein et al. , 1993 Jackisch et al. 1999) , GABA (Forray et al. 1999; Alachkar et al. 2006) , and dopamine (Millan et al. 2000; Fox et al. 2008) . Interactions between other neurotransmitters (Gilsbach and Hein 2012) might thus also contribute to the effect of clonidine. We would point out, however, that these results apply to idiopathic PD patients, and that conclusions might be slightly different for other subtypes of PD.
Clues about the functional role of STN in response inhibition
Our results also provide insights about the unclear anatomic and functional bases of the cortico-subthalamic system (Mathai and Smith 2011) , the disputed roles of the STN in motor control and response inhibition (Cui et al. 2013; Benis et al. 2016) , and the disputed mechanisms of action of STN-DBS (Udupa and Chen 2015) . Classically, the STN is thought to relay a stop signal via the hyperdirect pathway when the stimulus that subjects must refrain from reacting to has been identified (Aron and Poldrack 2006; Aron et al. 2007) . Our data clearly demonstrate that response inhibition does not only rely on this kind of reactive, fast braking signal, since our design offers no possible confound with any reactive and selective inhibitory activity (Criaud et al. 2017) . This means that the tonic activity of the STN might play a substantial role in inhibitory control, possibly via the indirect pathway, but maybe also via the hyperdirect pathway, as suggested by the tight coupling between STN-DBS and SMA tonic activity. Recent studies using intracerebral recordings also support the idea of a substantial role of the STN in proactive inhibition (Alegre et al. 2013; Benis et al. 2014 ).
Clues about the mechanisms of action of STN-DBS STN-DBS might not act by restoring normal activity into the thalamo-cortical loops via orthodromic effects on downstream targets within the basal ganglia, as initially suggested (Benabid et al. 2000) . Our data are consistent with the hypothesis that an antidromic stimulation of the corticosubthalamic projections by STN-DBS induces cortical activation that directly contributes to the therapeutic effect (Li et al. 2007 (Li et al. , 2014 Gradinaru et al. 2009; Kuriakose et al. 2010) . Because of the numerous interconnections between layer V neurons and local interneurons via axon collaterals, such antidromic effects would disrupt synchronized firing in the motor cortex. In PD, STN-DBS-induced antidromic action would contribute to restoring motor control by offsetting abnormal firing of the motor cortical neurons. The SMA is especially concerned with possible antidromic activation because it has direct projections to the STN (Li et al. 2007 (Li et al. , 2014 . The alpha band activity is especially targeted by the possible invasion of the antidromic spikes into the projection neurons because the local circuitry of the SMA involves a large proportion of inhibitory neurons (ibid). Our data, showing strong effects of STN-DBS in the alpha activity of the SMA, are thus consistent with this hypothetical mechanism of action of STN-DBS. This finding might facilitate the development of other therapeutic interventions, or improve currently unsatisfactory solutions, for instance by providing an accurate target for DBS closed loop approaches (Hariz 2014) or direct cortical stimulation (Strafella et al. 2007 ).
Conclusion
While NA has long been considered as having a minor influence on STN regulation (Parent and Hazrati 1995; Benarroch 2008 Benarroch , 2009 ), thanks to the combined use of STN-DBS and EEG recordings, our results provide evidence in humans of NA-dependent activity of the subthalamicsupplementary motor loop. The effects of clonidine assessed here are related to inhibitory control, the keystone of executive functions, and account for difficulties initiating actions. These results might open the way toward the development of non-dopaminergic therapies, an important area of research for idiopathic PD (Fox 2013; Espay et al. 2014; Kehagia et al. 2014) . More generally, various clinical symptoms ranging from akinetic freezing to motor impulsivity, which probably represent the opposite ends of the same continuum of executive dysfunction, might benefit from different medications targeting NA dysfunction in various neurologic and psychiatric conditions. Obviously, this study only provides novel insight into the neurobiological mechanisms by which NA pharmacological agents might exert influence on motor and executive functions, and further clinical investigations are warranted to extend the therapeutic use of the existing drugs targeting the NA system in the different clinical populations showing similar symptoms.
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